RxPONDER
clinical trial key findings presented at San Antonio Breast Cancer Symposium
December 8-11, 2020
RxPONDER at SABCS 2020

The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX®test


RxPONDER clinical trial key findings*


  • The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
  • Postmenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
  • Premenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 significantly benefit from chemotherapy
  • RxPONDER study results are expected to be practice-changing for postmenopausal N1 HR+, HER2-, early breast cancer patients

* Kalinsky et al. San Antonio Breast Cancer Symposium 2020, GS3-00

RxPONDER clinical trial design


  • RxPONDER, independently led by the SWOG Cancer Research Network, is one of the largest clinical trials for patients with HR+, HER2- early breast cancer and N1 disease
  • The trial was designed to determine the effect of chemotherapy, if any, in patients who had a Recurrence Score® result 0-25


Read our RxPONDER press release here

Product Industry Theatre Video

"Yes or No? Answering CT and ET Questions Through a Case-based Discussion with the Oncotype DX® test" with speakers: Jeremy Force, DO, Alison Stopeck, MD and Christy Russell, MD.

Other presentations of interest on
the Oncotype DX® Breast Recurrence Score Test


SWOG S1007: adjuvant trial randomized ER+ patients who had a Recurrence Score <25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy

VIEW OUR RxPONDER PRESS RELEASE

A prospective multicenter study evaluating the impact of the 21-gene Breast Recurrence Score upon physician treatment decision and cost in N+ breast cancer patients in Quebec
Abstract | Hassan

An analysis of the clinical and economic impact of the 21-gene Recurrence Score in invasive lobular early-stage breast cancer in Ireland
Abstract | Tharmabala

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Frist efficacy results from the ADAPT HR+/HER2- trial
Abstract | Harbeck

Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer
Abstract | Sparano

VIEW OUR PRESS RELEASE FOR RSCLIN AND ADAPT

ADAPTlate: A randomized, controlled, open-label, phase-III trial on adjuvant dynamic marker-adjusted personalized therapy comparing abemaciclib combined with standard adjuvant ER versus standard adjuvant ER in (clinical or genomic) high risk, HR+/HER2- early breast cancer
Abstract | Gluz

The feasibility of obtaining Oncotype DX Breast Recurrence Score results from the metastatic sites of patients with HR+ metastatic breast cancer
Abstract | Gemmill

Can genomic profiling eliminate the need for SLNB in ER+, T1-2 breast cancer
Abstract | Jackson

Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc.
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.